WHO ICTRP trial
Comparison of subcutaneous and intravenous retreatment with ultra-low dose…
NL-OMON52719 · Overview of Medical Research in the Netherlands (NL-OMON) · Recruiting
Key facts
| Trial ID | NL-OMON52719 |
|---|---|
| Public title | Comparison of subcutaneous and intravenous retreatment with ultra-low dose rituximab in rheumatoid arthritis: a randomised open-label non-inferiority trial |
| Scientific title | Comparison of subcutaneous and intravenous retreatment with ultra-low dose rituximab in rheumatoid arthritis: a randomised open-label non-inferiority trial - RTX-SC |
| Primary sponsor | Sint Maartenskliniek |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 4 |
| Countries | The Netherlands |
| Conditions | arthritis rheumatic diseases rheumatoid arthritis;10003816;10023213;arthritis;rheumatic diseases;rheumatoid arthritis |
| Interventions | Patients will be randomised to rituximab 336 mg subcutaneously or 200 mg intravenous 4-5 months after having received their last dose of rituximab. Randomization will be stratified to the previous rituximab dose (200 or 500 mg) and the use… |
| Registration date | Feb 22, 2022 |
| Target size | 36 |
| Secondary IDs | 2020-002507-19;NL74149.091.20 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: